Literature DB >> 27819842

Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia: A Case Series.

Davangere P Devanand1, Gregory H Pelton, Kristina D'Antonio, Jesse G Strickler, William C Kreisl, James Noble, Karen Marder, Anne Skomorowsky, Edward D Huey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27819842      PMCID： PMC5322244          DOI： 10.1097/WAD.0000000000000161

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN： 0893-0341            Impact factor:   2.703


× No keyword cloud information.
  15 in total

1.  Caregiver burden in frontotemporal degeneration and corticobasal syndrome.

Authors:  Nicole Armstrong; Nicole Schupf; Jordan Grafman; Edward D Huey
Journal:  Dement Geriatr Cogn Disord       Date:  2013-09-10       Impact factor: 2.959

Review 2.  Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies.

Authors:  Adam L Boxer; Bradley F Boeve
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Oct-Dec       Impact factor: 2.703

3.  A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.

Authors:  D P Devanand; K Marder; K S Michaels; H A Sackeim; K Bell; M A Sullivan; T B Cooper; G H Pelton; R Mayeux
Journal:  Am J Psychiatry       Date:  1998-11       Impact factor: 18.112

4.  Delusions and hallucinations are associated with worse outcome in Alzheimer disease.

Authors:  Nikolaos Scarmeas; Jason Brandt; Marilyn Albert; Georgios Hadjigeorgiou; Alexandros Papadimitriou; Bruno Dubois; Maria Sarazin; Davangere Devanand; Lawrence Honig; Karen Marder; Karen Bell; Domonick Wegesin; Deborah Blacker; Yaakov Stern
Journal:  Arch Neurol       Date:  2005-10

5.  Successful treatment of dementia with lithium.

Authors:  W W Havens; J Cole
Journal:  J Clin Psychopharmacol       Date:  1982-02       Impact factor: 3.153

Review 6.  Lithium treatment at 52.

Authors:  M Schou
Journal:  J Affect Disord       Date:  2001-12       Impact factor: 4.839

Review 7.  A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia.

Authors:  Edward D Huey; Karen T Putnam; Jordan Grafman
Journal:  Neurology       Date:  2006-01-10       Impact factor: 9.910

8.  The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.

Authors:  Ira Katz; Peter-Paul de Deyn; Jacobo Mintzer; Andrew Greenspan; Young Zhu; Henry Brodaty
Journal:  Int J Geriatr Psychiatry       Date:  2007-05       Impact factor: 3.485

Review 9.  Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium.

Authors:  Antoni Camins; Ester Verdaguer; Felix Junyent; Marc Yeste-Velasco; Carme Pelegrí; Jordi Vilaplana; Mercé Pallás
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

10.  A feasibility and tolerability study of lithium in Alzheimer's disease.

Authors:  Alastair Macdonald; Kate Briggs; Michaela Poppe; Andrea Higgins; Latha Velayudhan; Simon Lovestone
Journal:  Int J Geriatr Psychiatry       Date:  2008-07       Impact factor: 3.485
View more
  10 in total

1.  Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.

Authors:  D P Devanand; Jesse G Strickler; Edward D Huey; Elizabeth Crocco; Brent P Forester; Mustafa M Husain; Ipsit V Vahia; Howard Andrews; Melanie M Wall; Gregory H Pelton
Journal:  Contemp Clin Trials       Date:  2018-05-31       Impact factor: 2.226

Review 2.  Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia.

Authors:  Christine Le; Elizabeth Finger
Journal:  CNS Drugs       Date:  2021-08-24       Impact factor: 5.749

3.  Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial.

Authors:  D P Devanand; Elizabeth Crocco; Brent P Forester; Mustafa M Husain; Seonjoo Lee; Ipsit V Vahia; Howard Andrews; Laura Simon-Pearson; Nadia Imran; Luminita Luca; Edward D Huey; Deborah A Deliyannides; Gregory H Pelton
Journal:  Am J Geriatr Psychiatry       Date:  2021-05-12       Impact factor: 4.105

Review 4.  Molecular Mechanisms Linking ALS/FTD and Psychiatric Disorders, the Potential Effects of Lithium.

Authors:  Fiona Limanaqi; Francesca Biagioni; Larisa Ryskalin; Carla L Busceti; Francesco Fornai
Journal:  Front Cell Neurosci       Date:  2019-10-04       Impact factor: 5.505

Review 5.  Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions.

Authors:  Claudia Carrarini; Mirella Russo; Fedele Dono; Filomena Barbone; Marianna G Rispoli; Laura Ferri; Martina Di Pietro; Anna Digiovanni; Paola Ajdinaj; Rino Speranza; Alberto Granzotto; Valerio Frazzini; Astrid Thomas; Andrea Pilotto; Alessandro Padovani; Marco Onofrj; Stefano L Sensi; Laura Bonanni
Journal:  Front Neurol       Date:  2021-04-16       Impact factor: 4.003

Review 6.  Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward.

Authors:  Sara Melisa Arciniegas Ruiz; Hagit Eldar-Finkelman
Journal:  Front Mol Neurosci       Date:  2022-01-21       Impact factor: 5.639

7.  The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents.

Authors:  Guy Griebel; Jeanne Stemmelin; Mati Lopez-Grancha; Denis Boulay; Gerald Boquet; Franck Slowinski; Philippe Pichat; Sandra Beeské; Shinji Tanaka; Akiko Mori; Masatake Fujimura; Junichi Eguchi
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

8.  Lithium alters expression of RNAs in a type-specific manner in differentiated human neuroblastoma neuronal cultures, including specific genes involved in Alzheimer's disease.

Authors:  Bryan Maloney; Yokesh Balaraman; Yunlong Liu; Nipun Chopra; Howard J Edenberg; John Kelsoe; John I Nurnberger; Debomoy K Lahiri
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

Review 9.  Psychosis in Alzheimer's Disease.

Authors:  Clive Ballard; Helen C Kales; Constantine Lyketsos; Dag Aarsland; Byron Creese; Roger Mills; Hilde Williams; Robert A Sweet
Journal:  Curr Neurol Neurosci Rep       Date:  2020-10-13       Impact factor: 5.081

Review 10.  A review of the mechanisms underlying selected comorbidities in Alzheimer's disease.

Authors:  Karolina Maciejewska; Kamila Czarnecka; Paweł Szymański
Journal:  Pharmacol Rep       Date:  2021-06-13       Impact factor: 3.024
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.